Wilson Sonsini is pleased to sponsor the 7th In-House Impact: Biopharma Summit, a premier gathering designed exclusively for general counsels, chief legal officers, and senior in-house legal leaders across the biopharma industry.

Over two focused days, this summit convenes legal decision-makers to address the most consequential challenges facing biopharma companies in 2026. Sessions will cover navigating FDA regulatory uncertainty, drug pricing reform, AI adoption and governance, IP protection strategies, compliance program maturity, and cross-border legal risk. Presentations are led by GCs and CLOs from some of the industry's most innovative companies, offering peer-level insight and benchmarking that is difficult to replicate in any other setting.

Wilson Sonsini partner Chris McAndrew will speak on a panel addressing IP and gene editing.